LIM and SH3 domain protein 1 Polyclonal Antibody

Rabbit Anti-LIM and SH3 domain protein 1 Polyclonal Antibody

Product Specifications

Background

LASP1 encodes a member of a subfamily of LIM proteins, characterized by a LIM motif and a domain of Src homology region 3, and also a member of the nebulin family of actin-binding proteins. The encoded protein is a cAMP and cGMP dependent signaling protein and binds to the actin cytoskeleton at extensions of the cell membrane. The encoded protein has been linked to metastatic breast cancer, hematopoetic tumors such as B-cell lymphomas, and colorectal cancer.

CAS Number

9007-83-4

Product Name Alternative

LIM and SH3 domain protein 1; LASP-1; Metastatic lymph node gene 50 protein; MLN 50

Gene ID

3927

Accession Number

Q14847

Reactivity

Human, Mouse, Rat

Immunogen

Synthesized peptide derived from part region of human LIM and SH3 domain protein 1 protein at amino acid sequence of 90-130

Clonality

Polyclonal

Tag

LIM and SH3 domain protein 1

Applications

WB, IHC

Purification Method

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration

1 mg/ml

Molecular Weight

38kD

Precautions

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Shipping Conditions

Gel pack with blue ice.

Storage Conditions

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Notes

This antibody detects endogenous levels of LIM and SH3 domain protein 1

Observed Molecular Weight

Formulation

Liquid solution

Buffer pH

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Applications Notes

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-2000; IHC 1:50-300